ICLR vs GH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ICLR · Icon PLC$204.74 ▲ 1.53%
GH · Guardant Health$150.87 ▼ 1.67%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ICLR +29.8%
- GH +54.1%
Head to head
| Metric | ICLR | GH |
|---|---|---|
| Price | $204.74 | $150.87 |
| Change today | ▲ 1.53% | ▼ 1.67% |
| Market cap | $15.34B | $20.41B |
| Return, 3 months | +23.3% | -9.8% |
| Return, year to date | +12.4% | +47.7% |
| Return, 1 year | +28.7% | +56.0% |
| P/E (TTM) | 35.5 | – |
| P/B | 1.7 | -74.0 |
| P/E percentile vs own 5y | 39th | 8th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +1.2% | +44.3% |
| Net profit growth (YoY) | -64.3% | -20.3% |
| Gross margin | 23.9% | 65.0% |
| Operating margin | 10.1% | -39.7% |
| Net margin | 0.5% | -38.3% |
| Return on equity | 0.4% | – |
| Analyst target vs. price | +15.9% | +35.3% |
| Analyst buy share | 58% | 100% |
| RSI (14) | 66 | 37 |
| 30-day volatility | 59.3% | 55.1% |
| Max drawdown, 1 year | -60.5% | -33.0% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GH is the largest of the group by market value.
- GH has returned the most over the past year.
- GH is growing revenue fastest.
- ICLR keeps the most profit per dollar of sales.
- GH has been the calmest stock over the last 30 days.